---
title: "Seaport and Hemab target $180m IPOs as biotech listings accumulate"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284375788.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-04-28T10:22:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284375788.md)
  - [en](https://longbridge.com/en/news/284375788.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284375788.md)
---

# Seaport and Hemab target $180m IPOs as biotech listings accumulate

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [426CVR015TMP.US](https://longbridge.com/en/quote/426CVR015TMP.US.md)
- [COEP.US](https://longbridge.com/en/quote/COEP.US.md)
- [NBSE.ESC.US](https://longbridge.com/en/quote/NBSE.ESC.US.md)
- [SEELQ.US](https://longbridge.com/en/quote/SEELQ.US.md)
- [SEEL.US](https://longbridge.com/en/quote/SEEL.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [SEG.US](https://longbridge.com/en/quote/SEG.US.md)

## Related News & Research

- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Korro Bio To Advance KRRO-111 As Potential Treatment For AATD](https://longbridge.com/en/news/287089978.md)
- [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)